0001209191-18-057556.txt : 20181107
0001209191-18-057556.hdr.sgml : 20181107
20181107160906
ACCESSION NUMBER: 0001209191-18-057556
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181105
FILED AS OF DATE: 20181107
DATE AS OF CHANGE: 20181107
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Biller Scott
CENTRAL INDEX KEY: 0001581956
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36014
FILM NUMBER: 181166383
MAIL ADDRESS:
STREET 1: C/O AGIOS PHARMACEUTICALS, INC.
STREET 2: 38 SIDNEY STREET, 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001439222
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-8600
MAIL ADDRESS:
STREET 1: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-11-05
0
0001439222
AGIOS PHARMACEUTICALS INC
AGIO
0001581956
Biller Scott
C/O AGIOS PHARMACEUTICALS, INC.
88 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
Chief Scientific Officer
Common stock
2018-11-05
4
M
0
3000
9.05
A
53932
D
Common stock
2018-11-05
4
S
0
2200
69.44
D
51732
D
Common stock
2018-11-05
4
S
0
700
70.23
D
51032
D
Common stock
2018-11-05
4
S
0
100
71.42
D
50932
D
Common Stock
6264
I
See footnote
Stock options (right to buy)
9.05
2018-11-05
4
M
0
3000
0.00
D
2023-04-30
Common stock
3000
4154
D
This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $68.97 to $69.91. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $70.00 to $70.57. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Shares held by a spousal lifetime access trust, of which the reporting person's wife is trustee.
This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.
/s/ William Cook, as Attorney-in-fact for Scott Biller
2018-11-07